Transcriptomics

Dataset Information

0

A screening study identified decitabine as an inhibitor of Equid Herpesvirus 4 that enhances the innate antiviral response


ABSTRACT: Equid herpesvirus 4 (EHV-4) is a frequent respiratory pathogen of the horse. EHV-4 sporadically induces abortion or neonatal death and although not clearly demonstrated its involvement in neurological forms is strongly suspected. Despite preventive treatments using vaccines against EHV-1/EHV-4, the resurgence of α-EHV infection still constitutes an important threat to the horse industry. Yet very few studies have been conducted on the search for antiviral molecules against EHV-4. A screening of 42 antiviral compounds was performed in vitro on E. Derm cells infected with EHV-4 405/76 reference strain (VR2230). Formation of cytopathic effects was monitored by Real-Time Cell Analysis (RTCA) and the viral load was quantified by qPCR. Aciclovir, the most widely used antiviral in vivo against alpha-herpesviruses, does not appear to be effective against EHV-4 in vitro. Potential antiviral activities were confirmed for 8 molecules (idoxuridine, vidarabine, pritelivir, cidofovir, valganciclovir, ganciclovir, aphidicolin, and decitabine). Decitabine is the most potent compound against EHV-4 in vitro. A transcriptomic analysis revealed an increase of expression of different genes implicated in IFN response. Decitabine (DTB) seems to activate the immune antiviral pathway.

ORGANISM(S): Equus caballus

PROVIDER: GSE261894 | GEO | 2024/06/06

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

| 2005372 | ecrin-mdr-crc
2016-05-07 | GSE81219 | GEO
2020-06-01 | GSE142381 | GEO
2013-01-30 | E-MAXD-11 | biostudies-arrayexpress
2019-02-21 | GSE126813 | GEO
2024-08-14 | PXD053508 | Pride
| PRJNA1039337 | ENA
| PRJNA1123273 | ENA
2019-12-29 | GSE134709 | GEO
2023-04-07 | GSE229057 | GEO